GlassScriptPhysician profile
Brian Zeidan
NPI 1568050763
$4,304.25
in general payments reported to CMS, 2019-2025
40 companies · $371 in 2025
The $371 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $968 · 2023: $1,677 · 2024: $1,101 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,148.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $591.55 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $542.44 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $462.20 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $434.01 | 2021-2025 | |
| Abbvie INC. | $417.76 | 2021-2024 | Vraylar |
| Amgen INC. | $213.67 | 2021-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $172.49 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.54 | 2021-2023 | |
| Inspire Medical Systems, INC. | $141.82 | 2023 | Inspire |
| Daiichi Sankyo INC. | $131.18 | 2023-2025 | Injectafer |
| Philips North America LLC | $126.51 | 2023-2025 | (Ck7) Extended Holter, Extended Holter, Event |
| Vanda Pharmaceuticals INC. | $92.29 | 2022-2023 | Hetlioz |
| Abbott Laboratories | $88.72 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.54 | 2022-2024 | Tradjenta, Jardiance |
| Astrazeneca Pharmaceuticals LP | $78.60 | 2023-2025 | Farxiga, Airsupra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $41.98 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $41.27 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.44 | 2024 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $35.55 | 2024 | Onpattro |
| Coloplast Corp | $32.90 | 2022 | |
| Lucid Diagnostics INC. | $32.57 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.93 | 2021 | |
| Boston Scientific Corporation | $24.30 | 2023 | Watchman Access System |
| Abiomed | $24.24 | 2023 | Impella |
| Viatris Specialty LLC | $23.38 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $22.45 | 2024 | Gemtesa |
| Bausch Health US, LLC | $20.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.06 | 2023 | Crysvita |
| Merck Sharp & Dohme LLC | $20.00 | 2022 | |
| Horizon Therapeutics Plc | $19.07 | 2021 | |
| Averitas Pharma INC. | $18.05 | 2023 | Qutenza |
| Inari Medical, INC. | $17.19 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kowa Pharmaceuticals America, INC. | $15.80 | 2022 | |
| Almatica Pharma LLC | $14.86 | 2022 | |
| Amarin Pharma, INC. | $14.53 | 2022 | |
| Medtronic, INC. | $14.46 | 2024 | Intellis Adaptivestim |
| Shield Therapeutics INC | $14.18 | 2024 | |
| Nevro Corp. | $13.64 | 2024 | Senza |
| Linus Health, INC. | $13.46 | 2024 | Core Cognitive Evaluation |
| Kyowa Kirin, INC. | $12.82 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Zeidan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.